PHSC 5500 — Repurposing Drugs for Cancer Immunotherapies
2 semester hoursGraduateLectureusually offered: springtypical days: WBostonTraditional
Offers a multidisciplinary course targeted to students interested in recent advances in biomedical research, clinical practice, and personalized medicine as related to cancer immunotherapies. Describes current promises and disappointments with cancer immunotherapies and recent FDA drug approvals for personalized cancer therapies. Explains the role of immunological and physiological negative regulators of antitumor and tumor biology as needed. Explains underlying principles of immunology, biochemistry, genetics, and preclinical and clinical studies when introducing new concepts. Assigned detailed study of specific areas and discussion of assigned papers are designed to complement classroom material.
Offering history
| Term | Sections | Enrolled | Capacity | Full | Open seats/section |
|---|---|---|---|---|---|
| Spring 2024 | 1 | 18 | 25 | 72% | 7.0 |
| Spring 2025 | 1 | 19 | 25 | 76% | 6.0 |
Snapshots from scheduled scrapes — not live seat availability. "Full" can exceed 100% when sections over-enroll.
Meeting times
Share of recent sections by weekday: M 0% · T 0% · W 100% · Th 0% · F 0%
Common patterns: W (100% of sections) — in patterns, R means Thursday
Professors
Spring
- Michail Sitkovsky (100% of students) · reviews
Percentages are each professor's average share of the season's enrolled students in recent terms.
Unlocks
Courses that list PHSC 5500 in their prerequisites.
Links
Official catalog (PHSC course descriptions) · Student reviews on RateMyHusky · All PHSC courses · Plan it at numap.app